SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 177 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $58,080,000 | -14.9% | 4,000,000 | +22.6% | 9.50% | +1.2% |
| Q2 2023 | $68,273,744 | +0.8% | 3,262,004 | +1.7% | 9.39% | +7.4% |
| Q1 2023 | $67,710,424 | +3.9% | 3,205,986 | +25.2% | 8.74% | -12.6% |
| Q4 2022 | $65,182,209 | +19.3% | 2,561,187 | +12.7% | 10.00% | -13.1% |
| Q3 2022 | $54,618,000 | +13.0% | 2,272,915 | -9.5% | 11.51% | -6.8% |
| Q2 2022 | $48,335,000 | +43.9% | 2,512,240 | +30.0% | 12.34% | +13.3% |
| Q1 2022 | $33,592,000 | +60.5% | 1,932,800 | +102.1% | 10.90% | -2.6% |
| Q4 2021 | $20,930,000 | – | 956,165 | – | 11.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |